CryLife inks deal to buy Cardiogenesis

Friday, April 1, 2011

Atlanta, Ga.-based CryoLife, a biological medical device company, has signed a deal to buy Cardiogenesis for $22 million, according to FierceMedicalDevices. The Irvine, Calif.-based developer develops surgical products for patients with refractory angina as a result of diffuse coronary artery disease. Cardiogenesis’ technology is used for Transmyocardial Revascularization (TMR), which treats patients with angina that is not responsive to medications.

[Read More]